-Educate patient to report worsening immediately. -If worsens: Treat as Grade 2, 3 or 4. Grade 2 Diarrhea: 4 to 6 stools perdayover Baseline; IVfluids indicated <24 hours; not interfering with ADL Colitis: abdominal pain; blood instool-Withhold study treatment. -Symptomatic treatment.-Ifimproves toGrade ≤1:Resume study treatment. -Ifpersists >5 -7 days or recurs: Treat asGrade 3or 4. Grade 3to 4 Diarrhea (Grade 3): ≥7 stools per day over Baseline; incontinence; IV fluids ≥24 h; interfering with ADL Colitis (Grade 3): severe abdominal pain, medical intervention indicated, peritoneal signs Grade 4: life- threatening, perforation-Withhold for Gr ade 3. -Perm anently discontinue study treatment for Grade 4 or recurrent Grade 3. -1.0 to 2.0 mg/kg/day prednisone IV or equivalent. -Add prophylactic antibiotics for opportunistic infections. -Consider lower endoscopy.-Ifimproves: -Continue steroids unt il Grade ≤1, then taper over at least 1 month; resume study treatment following steroids taper (for initial Grade 3). -If worsens, persists >3 to 5 days, or recurs after improvement: -Add infliximab 5mg/kg (if no contraindication). -Note: infliximab should not be used in cases of perforation or sepsis. PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 157Derm atological irAEs Grade of Rash (NCI -CTCAE v5.0)Initial Managem ent Follow -up Managem ent Grade 1to 2 Covering ≤30% body surface area-Continue study treatment. -Symptomatic therapy (for example, antihistamines, topical steroids).-If persists >1 to 2 w eeks or recurs: -Withhold study treatment; -Consider skin biopsy. -Consider 0.5 -1.0 mg/kg/day prednisone or equivalent. Once improving, taper steroids over at least 1 month, consider prophylactic antibiotics for opportunistic infections, and resume study treatment following steroids taper. -If worsens: Treat as Grade 3 to 4. Grade 3to 4 Grade 3: Covering >30% body surface area; Grade 4: Life threatening consequences-Withhold study treatment for Grade 3. -Perm anently discontinue for Grade 4 or recurrent Grade 3. -Consider skin biopsy. -Derm atology consult. -1.0 to 2.0 mg/kg/day prednisone or equivalent. -Add prophylactic antibiotics for opportunistic infections.-If improves to Grade ≤1: -Taper steroids over at least 1 month; resume study treatment following steroids taper (for initial Grade 3). PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 158Pulmonary irAEs Grade of Pneumonitis (NCI -CTCAE v5.0)Initial Managem ent Follow -up Managem ent Grade 1 Radiographic changes only-Consider withholding study treatment. -Monitor for symptoms every 2 to 3 days. -Consider Pulmonary and Infectious Disease consults.-Re-assess at least every 3 weeks. -If worsens: Treat as Grade 2 or Grade 3 to 4. Grade 2 Mild to moderate new symptoms-Withhold study treatment. -Pulmonary and Infectious Disease consults. -Monitor symptoms daily; consider hospitalization. -1.0 to 2.0 mg/kg/day prednisone or equivalent. -Add prophylactic antibiotics for opportunistic infections. -Consider bronchoscopy, l ung biopsy.-Re-assess every 1 to 3 days If improves: -When symptoms return to Grade ≤1, taper steroids over at least 1 month, and then resume study treatment following steroids taper. -If not improving after 2 weeks or worsening: Treat as Grade 3 to 4. Grade 3to 4 Grade 3: Severe new symptoms; New/w orsening hypoxia; Grade 4: Life -threatening-Permanently discontinue study treatment. -Hospitalize.